NNovartis Read More ChrysCapital acquires 70.68% stake in Novartis India Limited2026-08-03 ChrysCapital acquires 70.68% stake in Novartis India Limited July 30, 2026 | Thursday | News Acquisition marks ChrysCapital’s…
NNovartis Read More ChrysCapital acquires 70.68% stake in Novartis India Limited2026-08-01 ChrysCapital acquires 70.68% stake in Novartis India Limited July 30, 2026 | Thursday | News Acquisition marks ChrysCapital’s…
NNovartis Read More ChrysCapital acquires 70.68% stake in Novartis India2026-07-31 ChrysCapital acquires 70.68% stake in Novartis India July 30, 2026 | Thursday | News Acquisition marks ChrysCapital’s first…
NNovartis Read More Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics2026-07-06 MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) — Brandon Capital, Australasia’s leading life sciences venture capital firm, today…
SSwitzerland Read More TTM Technologies, Inc. to Acquire Privately-Held, European-Based Swiss Technology Group AG and ILFA GmbH2026-06-17 Acquisitions Would Establish TTM’s Presence in Europe, Adding Strategic PCB and Materials Capabilities in Medical, Aerospace & Defense,…
RRoche Read More Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics2026-05-08 PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche’s digital pathology…
NNovartis Read More Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation2026-03-27 – Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases – Lead asset…
SSwitzerland Read More SEALSQ Signs Letter of Intent to Acquire 100% of Miraex, a Swiss Quantum Interconnect Platform Company2026-03-24 Geneva, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) — Strategic Acquisition via the SEALSQ Quantum Fund Strengthens its Quantum…
NNovartis Read More Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline2026-03-20 Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…